MCID: LRG001
MIFTS: 48

Large Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Respiratory diseases, Skin diseases, Rare diseases

Aliases & Classifications for Large Cell Carcinoma

MalaCards integrated aliases for Large Cell Carcinoma:

Name: Large Cell Carcinoma 12 15
Carcinoma, Large Cell 44 73
Carcinoma Large Cell 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4552
MeSH 44 D018287
NCIt 50 C3780
SNOMED-CT 68 189551005 22687000
UMLS 73 C0206704

Summaries for Large Cell Carcinoma

Disease Ontology : 12 A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary : Large Cell Carcinoma, also known as carcinoma, large cell, is related to pleomorphic carcinoma and adenocarcinoma. An important gene associated with Large Cell Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Carboplatin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and thyroid, and related phenotypes are behavior/neurological and cellular

Related Diseases for Large Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 pleomorphic carcinoma 32.3 EGFR KRT7 NKX2-1
2 adenocarcinoma 30.1 EGFR FGFR1 ROS1 STK11
3 pulmonary large cell neuroendocrine carcinoma 29.2 CHGA ENO2 ROS1 STK11 SYP
4 adenoid cystic carcinoma 29.2 KRT7 NCAM1 TP63
5 lung squamous cell carcinoma 29.1 EGFR FGFR1 PTHLH ROS1 TP63
6 squamous cell carcinoma 29.0 EGFR PTHLH STK11 TP63
7 small cell carcinoma 28.1 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
8 large cell neuroendocrine carcinoma 28.0 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
9 adenosquamous carcinoma 27.5 EGFR KRT5 KRT7 NKX2-1 PTHLH TP63
10 lung cancer susceptibility 3 26.6 CEACAM5 EGFR KRT7 NKX2-1 SFTPB STK11
11 lung cancer 23.8 CEACAM5 CHGA EGFR ENO2 FGFR1 KRT7
12 lung large cell carcinoma 12.4
13 large cell carcinoma with rhabdoid phenotype 12.2
14 thymus large cell carcinoma 12.1
15 lung occult large cell carcinoma 12.0
16 lung mixed small cell and squamous cell carcinoma 11.0
17 solid adenocarcinoma with mucin production 10.9 KRT7 NKX2-1
18 adenoma of the pancreas 10.9 CHGA SYP
19 acinar cell cystadenocarcinoma 10.9 CHGA SYP
20 peritoneal serous adenocarcinoma 10.9 CHGA SYP
21 cellular ependymoma 10.9 CHGA SYP
22 primary hepatic neuroendocrine carcinoma 10.9 CHGA SYP
23 ovary neuroendocrine neoplasm 10.9 KRT7 SYP
24 embryoma 10.9 NKX2-1 SYP
25 gastrointestinal neuroendocrine tumor 10.9 CHGA SYP
26 ovarian germ cell teratoma 10.9 KRT7 NKX2-1
27 cystic basal cell carcinoma 10.8 KRT7 TP63
28 lung acinar adenocarcinoma 10.8 KRT7 NKX2-1
29 ovarian germ cell cancer 10.8 KRT7 NKX2-1
30 chordoid meningioma 10.8 CHGA SYP
31 intracranial primitive neuroectodermal tumor 10.8 CHGA ENO2
32 malignant sertoli cell tumor 10.8 ENO2 SYP
33 mucinous bronchioloalveolar adenocarcinoma 10.8 KRT7 NKX2-1
34 transverse colon cancer 10.8 DSC3 KRT7
35 sinonasal undifferentiated carcinoma 10.8 ENO2 SYP
36 lung combined type small cell carcinoma 10.8 NCAM1 SYP
37 pancreatic somatostatinoma 10.8 ENO2 SYP
38 cribriform carcinoma 10.8 KRT7 TP63
39 epithelioid malignant peripheral nerve sheath tumor 10.8 CHGA ENO2
40 papillary tumor of the pineal region 10.8 ENO2 SYP
41 rosette-forming glioneuronal tumor 10.8 FGFR1 SYP
42 sclerosing hepatic carcinoma 10.7 CHGA PTHLH
43 ovarian carcinosarcoma 10.7 ENO2 SYP
44 goblet cell carcinoid 10.7 CHGA ENO2
45 central nervous system primitive neuroectodermal neoplasm 10.7 ENO2 SYP
46 cerebellum cancer 10.7 ENO2 SYP
47 multiple mucosal neuroma 10.7 ENO2 NCAM1
48 subependymal glioma 10.7 ENO2 SYP
49 hypoganglionosis 10.7 NCAM1 SYP
50 renal adenoma 10.7 KRT7 NCAM1

Graphical network of the top 20 diseases related to Large Cell Carcinoma:



Diseases related to Large Cell Carcinoma

Symptoms & Phenotypes for Large Cell Carcinoma

MGI Mouse Phenotypes related to Large Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 KRT5 NCAM1 NKX2-1 ENO2 PTHLH FGFR1
2 cellular MP:0005384 10.16 PTHLH FGFR1 KRT7 NCAM1 EGFR NKX2-1
3 mortality/aging MP:0010768 10.06 PTHLH FGFR1 CHGA KRT5 DSC3 NCAM1
4 craniofacial MP:0005382 9.98 KRT5 EGFR ENO2 PTHLH FGFR1 STK11
5 digestive/alimentary MP:0005381 9.95 FGFR1 KRT5 EGFR NKX2-1 PTHLH STK11
6 integument MP:0010771 9.91 PTHLH FGFR1 KRT5 DSC3 EGFR TP63
7 no phenotypic analysis MP:0003012 9.86 ROS1 KRT5 CHGA EGFR NKX2-1 FGFR1
8 renal/urinary system MP:0005367 9.7 CHGA KRT7 EGFR PTHLH FGFR1 STK11
9 reproductive system MP:0005389 9.56 PTHLH FGFR1 CHGA EGFR NKX2-1 TP63
10 respiratory system MP:0005388 9.17 EGFR NKX2-1 ENO2 PTHLH SFTPB STK11

Drugs & Therapeutics for Large Cell Carcinoma

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2 41575-94-4 10339178 498142 38904
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Everolimus Approved Phase 4 159351-69-6 6442177
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2 33069-62-4 36314
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2
8 Anti-Bacterial Agents Phase 4
9 Antibiotics, Antitubercular Phase 4
10 Immunosuppressive Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Antifungal Agents Phase 4
13 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
14
Crizotinib Approved Phase 3,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
15 Mitogens Phase 3,Phase 1
16 Antibodies Phase 3,Phase 2
17 Immunoglobulins Phase 3,Phase 2
18 Antibodies, Monoclonal Phase 3,Phase 2
19 Protein Kinase Inhibitors Phase 3,Phase 1
20 insulin Phase 3
21
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
22 Insulin, Globin Zinc Phase 3
23 tyrosine Nutraceutical Phase 3,Phase 1
24
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
25
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
26
Etoposide Approved Phase 2 33419-42-0 36462
27
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
28
nivolumab Approved Phase 2 946414-94-4
29
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
30
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
31
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
32
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
motexafin gadolinium Investigational Phase 2,Phase 1 156436-89-4 12047567
35
Camptothecin Experimental Phase 2 7689-03-4
36 Pharmaceutical Solutions Phase 2,Phase 1
37 topoisomerase I inhibitors Phase 2
38 Topoisomerase Inhibitors Phase 2
39 Dermatologic Agents Phase 2,Phase 1
40 Vaccines Phase 1, Phase 2
41 Photosensitizing Agents Phase 2,Phase 1
42 Etoposide phosphate Phase 2
43 Alkylating Agents Phase 2
44 Folic Acid Antagonists Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Vitamin B Complex Phase 2
47 Antineoplastic Agents, Alkylating Phase 2
48 Folate Nutraceutical Phase 2
49 Vitamin B9 Nutraceutical Phase 2
50
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
2 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
3 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3 ZD6474 (vandetanib)
4 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Active, not recruiting NCT02737501 Phase 3 Brigatinib;Xalkori (crizotinib)
5 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
6 Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
7 A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Unknown status NCT01497041 Phase 2 Docetaxel;Oxaliplatin
8 A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer Completed NCT01362400 Phase 2 IPI 504 plus Docetaxel;Placebo plus Docetaxel
9 Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) Completed NCT00240097 Phase 2 Intervention A: Irinotecan; Oxaliplatin; Neulasta;Intervention B: Etoposide; Carboplatin; Neulasta
10 Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Completed NCT00073398 Phase 1, Phase 2
11 Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Recruiting NCT03110978 Phase 2 Nivolumab
12 Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) Terminated NCT01511081 Phase 2
13 Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer Terminated NCT00365183 Phase 2 Motexafin gadolinium and pemetrexed
14 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) Terminated NCT00632203 Phase 2 Temozolomide
15 A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) Completed NCT00102505 Phase 1 Motexafin Gadolinium Injection
16 An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer Completed NCT00054899 Phase 1
17 -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Terminated NCT01441128 Phase 1 PF-02341066/PF-00299804;PF-02341066/PF-00299804
18 Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer Withdrawn NCT01637376 Phase 1 Temoporfin
19 Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix Recruiting NCT01606293
20 Mass Spectral Fingerprinting in Lung Cancer Recruiting NCT02781857
21 Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy Active, not recruiting NCT02357992 Not Applicable
22 An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available NCT02784158 Brigatinib

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Genetic Tests for Large Cell Carcinoma

Anatomical Context for Large Cell Carcinoma

MalaCards organs/tissues related to Large Cell Carcinoma:

41
Lung, Cervix, Thyroid, Ovary, Prostate, Lymph Node, Brain

Publications for Large Cell Carcinoma

Articles related to Large Cell Carcinoma:

(show top 50) (show all 173)
# Title Authors Year
1
Large Cell Carcinoma with Adenocarcinoma in Lung. ( 29544586 )
2018
2
An Unusually Aggressive Large Cell Carcinoma of the Lung: Undiagnosed until Autopsy. ( 29682432 )
2018
3
Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. ( 29246019 )
2017
4
Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus. ( 28587298 )
2017
5
Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. ( 26818832 )
2016
6
The development of large-cell carcinoma in the wall of a giant bulla complicated by hemorrhage. ( 26964998 )
2016
7
BRAF mutations in sarcomatoid and large cell carcinoma of the lung. ( 27939777 )
2016
8
BRAF mutations in sarcomatoid and large cell carcinoma of the lung-reply. ( 27939780 )
2016
9
Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung. ( 27384989 )
2016
10
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria. ( 26430808 )
2016
11
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. ( 26186355 )
2015
12
USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. ( 25519684 )
2015
13
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. ( 25452802 )
2015
14
Close Relation of Large Cell Carcinoma to Adenocarcinoma by Hierarchical Cluster Analysis: Implications for Histologic Typing of Lung Cancer on Biopsies. ( 25789531 )
2015
15
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
16
Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. ( 25620799 )
2015
17
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. ( 26317919 )
2015
18
The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. ( 26543611 )
2015
19
Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung. ( 26345631 )
2015
20
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. ( 25937073 )
2015
21
Large cell carcinoma of lung: On the verge of extinction? ( 25023633 )
2014
22
Large cell carcinoma on the bullous wall detected in a specimen from a patient with spontaneous pneumothorax: report of a case. ( 25364539 )
2014
23
Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. ( 24811836 )
2014
24
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. ( 24384807 )
2014
25
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. ( 24221342 )
2014
26
Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung. ( 25085555 )
2014
27
Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. ( 23696935 )
2013
28
Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. ( 23738762 )
2013
29
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. ( 23196793 )
2013
30
Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung. ( 22284720 )
2012
31
Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. ( 22420949 )
2012
32
Mixed squamous and large-cell carcinoma of the lung: a case study and literature review. ( 23174733 )
2012
33
Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings. ( 22505007 )
2012
34
Primary undifferentiated large cell carcinoma of the lacrimal gland. ( 21276618 )
2011
35
Pulmonary large cell carcinoma mimicking an infected thoracoabdominal aortic aneurysm. ( 21847044 )
2011
36
Large cell carcinoma of the lacrimal gland diagnosed by fine needle aspiration biopsy. ( 22132846 )
2011
37
Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. ( 22031317 )
2011
38
Results of surgical resection for patients with large cell carcinoma of the lung. ( 20547250 )
2010
39
Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype. ( 20956201 )
2010
40
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
41
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
42
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. ( 19996214 )
2009
43
Large cell carcinoma of the lung and squamous cell carcinoma of the oropharynx presenting as uveitis. ( 19413230 )
2009
44
Cystic tumors of the right atrium caused by nonbacterial thrombotic endocarditis in a patient with large cell carcinoma. ( 19420823 )
2009
45
Large cell carcinoma of the lung: an endangered species? ( 19444077 )
2009
46
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. ( 19287461 )
2009
47
Immunohistochemical characterization of a pulmonary large-cell carcinoma in a dog. ( 18587094 )
2008
48
Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. ( 18364444 )
2008
49
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
50
Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. ( 17131342 )
2007

Variations for Large Cell Carcinoma

Expression for Large Cell Carcinoma

Search GEO for disease gene expression data for Large Cell Carcinoma.

Pathways for Large Cell Carcinoma

Pathways related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.09 ENO2 NCAM1 NKX2-1 SYP
2
Show member pathways
11.59 EGFR FGFR1 NCAM1
3 11.36 EGFR FGFR1 PTHLH
4 11.03 FGFR1 NCAM1 SYP
5 10.12 EGFR FGFR1 NCAM1

GO Terms for Large Cell Carcinoma

Cellular components related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 CEACAM5 CHGA DSC3 EGFR FGFR1 NCAM1

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.72 CEACAM5 EGFR FGFR1 ROS1 TP63
2 animal organ morphogenesis GO:0009887 9.65 NKX2-1 SFTPB TP63
3 negative regulation of signal transduction GO:0009968 9.63 EGFR FGFR1 ROS1
4 cornification GO:0070268 9.61 DSC3 KRT5 KRT7
5 lung development GO:0030324 9.58 EGFR FGFR1 NKX2-1
6 cerebral cortex cell migration GO:0021795 9.37 EGFR NKX2-1
7 positive regulation of kinase activity GO:0033674 9.33 EGFR FGFR1 ROS1
8 salivary gland morphogenesis GO:0007435 9.26 EGFR FGFR1
9 regulation of phosphate transport GO:0010966 8.96 FGFR1 ROS1
10 epidermis development GO:0008544 8.92 EGFR KRT5 PTHLH TP63

Molecular functions related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 EGFR FGFR1 NCAM1
2 MAP kinase kinase kinase activity GO:0004709 9.33 EGFR FGFR1 ROS1
3 mitogen-activated protein kinase kinase binding GO:0031434 9.13 EGFR FGFR1 ROS1
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR FGFR1 ROS1

Sources for Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....